Brand: Alhemo. API: concizumab-mtci is used to treat hemophilia A and hemophilia B.
Alhemo (concizumab-mtci) is a prescription subcutaneous (under the skin) injection used for routine daily prophylaxis (prevention) to stop or reduce the frequency of bleeding episodes
| Brand Name: | Alhemo – On Request |
| Generic Name: | concizumab-mtci |
| Strength: | Injection: 60 mg/1.5 mL (40 mg/mL) in a single-patient-use prefilled pen 150 mg/1.5 mL (100 mg/mL) in a single-patient-use prefilled pen 300 mg/3 mL (100 mg/mL) in a single-patient-use prefilled pen |
| Manufacturer: | Novo Nordisk Inc. |
| Approved By: | EMA, USFDA |
| Get access to medicines: | In India |
| Price: | On Request |
See full prescribing information for Alhemo: Patient Information
Get access Alhemo to treat hemophilia A and hemophilia B on a Named Patient Import Basis.
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Alhemo (concizumab-mtci) for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.